Anxiety and depression among AL amyloidosis patients: The role of cardiac symptoms

Amyloid

Volumn 19, Issue 3, 2012, Pages 123-128

  Smorti, Martina ^a   Cappelli, Francesco ^b   Bergesio, Franco ^b   Perfetto, Federico ^b  

^a FREE UNIVERSITY OF BOZEN BOLZANO   (Italy)

^b CAREGGI UNIVERSITY HOSPITAL   (Italy)

Author keywords

AL amyloidosis; Anxiety; Cardiological symptoms; Depression

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; TROPONIN;

ADULT; AGED; AMYLOIDOSIS; ANXIETY DISORDER; ARTICLE; CENTER FOR EPIDEMIOLOGICAL STUDIES DEPRESSION SCALE; CLINICAL ARTICLE; DEPRESSION; DISEASE ASSOCIATION; DISEASE SEVERITY; DISTRESS SYNDROME; ECHOCARDIOGRAPHY; FEMALE; GENERAL HEALTH QUESTIONNAIRE; HEART DISEASE; HUMAN; MALE; MENTAL STRESS; PRIORITY JOURNAL; QUESTIONNAIRE; STATE TRAIT ANXIETY INVENTORY; SYMPTOM;

AGED; AGED, 80 AND OVER; AMYLOIDOSIS; ANXIETY; DEPRESSION; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; QUESTIONNAIRES; REGRESSION ANALYSIS; STATISTICS, NONPARAMETRIC; STRESS, PSYCHOLOGICAL;

EID: 84865244950     PISSN: 13506129     EISSN: 17442818     Source Type: Journal    
DOI: 10.3109/13506129.2012.687420     Document Type: Article

References (33)

1. Gertz MA. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management. Am J Hematol 2011;86:180-186.
2. Palladini G, Campana C, Klersy C, Balduini A, Vadacca G, Perfetti V, Perlini S, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107:2440-2445. (Pubitemid 36605226)
3. Merlini G, Palladini G. Amyloidosis: is a cure possible? Ann Oncol 2008;19 Suppl 4:63-66.
4. Skinner M. AL amyloidosis: the last 30 years. Amyloid 2000;7:13-14. (Pubitemid 30317620)
5. Rapezzi C, Merlini G, Quarta CC, Riva L, Longhi S, Leone O, Salvi F, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-1212.
6. Kyle RA, Gertz MA. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32:45-59. (Pubitemid 24370135)
7. Telles-Correia D, Barbosa A, Mega I, Direitinho M, Morbey A, Monteiro E. Psychiatric differences between liver transplant candidates with familial amyloid polyneuropathy and those with alcoholic liver disease. Prog Transplant 2008;18:134-139. (Pubitemid 351847602)
8. Telles-Correia D, Barbosa A, Mega I, Mateus E, Monteiro E. Psychosocial determinants of quality of life 6 months after transplantation: longitudinal prospective study. Transplant Proc 2009;41:898-900.
9. Graceffa A, Russo M, Vita GL, Toscano A, Dattola R, Messina C, Vita G, Mazzeo A. Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy. Neuromuscul Disord 2009;19:44-48.
10. Paneque M, Lemos C, Sousa A, Velazquez L, Fleming M, Sequeiros J. Role of the disease in the psychological impact of pre-symptomatic testing for SCA2 and FAP ATTRV30M: Experience with the disease, kinship and gender of the transmitting parent. J Genet Couns 2009;18:483-493.
11. Heo S, Moser DK, Lennie TA, Zambroski CH, Chung ML. A comparison of health-related quality of life between older adults with heart failure and healthy older adults. Heart Lung 2007;36:16-24. (Pubitemid 46096594)
12. Heo S, Doering LV, Widener J, Moser DK. Predictors and effect of physical symptom status on health-related quality of life in patients with heart failure. Am J Crit Care 2008;17:124-132.
13. Friedman MM, Griffin JA. Relationship of physical symptoms and physical functioning to depression in patients with heart failure. Heart Lung 2001;30:98-104. (Pubitemid 32225933)
14. Bengtsson I, Hagman M, Wedel H. Age and angina as predictors of quality of life after myocardial infarction: a prospective comparative study. Scand Cardiovasc J 2001;35:252-258.
15. Christiaans I, van Langen IM, Birnie E, Bonsel GJ, Wilde AA, Smets EM. Quality of life and psychological distress in hypertrophic cardiomyopathy mutation carriers: a cross-sectional cohort study. Am J Med Genet A 2009;149A:602-612.
16. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, Greipp PR, et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol 2004;22:3751-3757. (Pubitemid 41095215)
17. Dispenzieri A, Gertz MA, Kyle RA, Lacy MQ, Burritt MF, Therneau TM, McConnell JP, et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004;104:1881-1887. (Pubitemid 39202301)
18. Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, et al. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol 1992;19:1550-1558.
19. Piccinelli M, Bisoffi G, Bon MG, Cunico L, Tansella M. Validity and test-retest reliability of the Italian version of the 12-item General Health Questionnaire in general practice: a comparison between three scoring methods. Compr Psychiatry 1993;34:198-205. (Pubitemid 23170659)
20. Goldberg D, Williams P. A user's guide to the General Health Questionnaire. Windsor: NFER-Nelson; 1988.
21. Goldberg DP, Gater R, Sartorius N, Ustun TB, Piccinelli M, Gureje O, Rutter C. The validity of two versions of the GHQ in the WHO study of mental illness in general health care. Psychol Med 1997;27:191-197. (Pubitemid 27042731)
22. Jacob KS, Bhugra D, Mann AH. The validation of the 12-item General Health Questionnaire among ethnic Indian women living in the United Kingdom. Psychol Med 1997;27:1215-1217. (Pubitemid 27401843)
23. Penninkilampi-Kerola V, Miettunen J, Ebeling H. A comparative assessment of the factor structures and psychometric properties of the GHQ- 12 and the GHQ-20 based on data from a Finnish population-based sample. Scand J Psychol 2006;47:431-440. (Pubitemid 44439092)
24. Sanchez-Lopez M, del P, Dresch V. The 12-Item General Health Questionnaire (GHQ-12): reliability, external validity and factor structure in the Spanish population. Psicothema 2008;20:839-843.
25. Pedrabissi L, Santinello M. STAI state-trait anxiety inventory - forma Y. Firenze: Giunti OS; 1989.
26. Speilberger CD. State-trait anxiety inventory manual. Palo Alto, CA: Mind Garden Inc; 1983.
27. Fava GA. Versione italiana del CES-D per la valutazione degli stati depressivi. Firenze: Giunti OS; 1982.
28. Radloff LS. The CES-D scale. A self-report depression scale for research in the general population. Appl Psychol Meas 1977;1:385-401.
29. Zagalo-Cardoso JA, Rolim L. Aspectos Psicossociais da Medicina Preditiva: Revisao da Literatura sobre Testes de Riscos Geneticos. Psicologia, Saude e Doencas 2005;6:3-34.
30. Dempsey SJ, Dracup K, Moser DK. Women's decision to seek care for symptoms of acute myocardial infarction. Heart Lung 1995;24:444-456.
31. Eaton WW, Anthony JC, Gallo J, Cai G, Tien A, Romanoski A, Lyketsos C, Chen LS. Natural history of Diagnostic Interview Schedule/DSM-IV major depression. The Baltimore Epidemiologic Catchment Area follow- up. Arch Gen Psychiatry 1997;54:993-999. (Pubitemid 27476094)
32. Hendriks GJ, Keijsers GP, Kampman M, Verbraak MJ, Broekman TG, Hoogduin CA, Oude Voshaar RC. [Treatment of anxiety disorders in the elderly]. Tijdschr Psychiatr 2011;53:589-595.
33. Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, Dingli D, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood 2012;119:1117-1122.